Lung inflammation and pulmonary function in infants with meconium aspiration syndrome

Rowena G Cayabyab1, Kenny Kwong, Craig Jones

  • 1Division of Neonatal Medicine, Department of Pediatrics, LAC+USC Medical Center, University of Southern California, Keck School of Medicine, Los Angeles, California, 90033, USA. cayabyab@usc.edu

Pediatric Pulmonology
|August 28, 2007
PubMed
Abstract

Insights

Meconium aspiration syndrome (MAS) involves inflammation with high cell counts and cytokines. Lung inflammation improves pulmonary function by 96 hours, indicated by reduced airway pressure and oxygenation index.

Area of Science:

  • Neonatal Medicine
  • Respiratory Physiology
  • Immunology

Background:

  • Meconium aspiration syndrome (MAS) is a significant cause of respiratory distress in term neonates.
  • Inflammation plays a critical role in the pathophysiology of MAS, impacting lung function.

Purpose of the Study:

  • To investigate the relationship between inflammatory markers and pulmonary function in neonates with MAS.
  • To quantify changes in cellular profiles, pro-inflammatory cytokines, and respiratory parameters over time.

Main Methods:

  • Studied 16 term infants with MAS.
  • Analyzed tracheal aspirates for cellular counts and pro-inflammatory cytokines (IL-1beta, IL-6, IL-8, TNF-alpha) via RT-PCR and ELISA at 6, 24, 48, and 96 hours of life.
  • Monitored pulmonary function parameters including mean airway pressure, oxygenation index (OI), and alveolar-arterial oxygen gradient.

Main Results:

  • Pulmonary function improved, with significant decreases in mean airway pressure (P=0.01) and OI (P=0.027) from 6 to 96 hours.
  • Tracheal aspirate cell counts decreased significantly from 17.4 x 10(6)/ml at 6 hours to 1.5 x 10(6)/ml at 96 hours (P<0.05).
  • Pro-inflammatory cytokine levels (IL-1beta, IL-6, IL-8) also showed significant reductions by 96 hours (P<0.05).

Conclusions:

  • MAS is characterized by an initial inflammatory response with elevated cellular and cytokine levels.
  • A decrease in lung inflammation by 96 hours correlates with improved pulmonary function, evidenced by reduced mean airway pressure and OI.
  • These findings highlight the dynamic inflammatory process in MAS and its impact on respiratory outcomes.

Related Concept Videos

Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features01:24

Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features

Chronic bronchitis is a key phenotype of chronic obstructive pulmonary disease (COPD), characterized by airway-centered inflammation and mucus overproduction. It develops from long-term exposure to harmful particles or gases, most commonly cigarette smoke, which triggers a persistent inflammatory response.Cellular and Structural ChangesInflammation initially affects the large bronchi and later the smaller airways, with infiltration by immune cells, including neutrophils, macrophages, and...
Pulmonary Cycle: Exhalation01:17

Pulmonary Cycle: Exhalation

In terms of human respiration, the act of expelling air, known as exhalation (or expiration), operates on the principle of pressure gradients. During expiration, the pressure within the lungs exceeds that of the surrounding atmosphere. Under normal conditions, quiet breathing involves passive exhalation and is free of muscular contractions. This is because the exhalation process is driven by the natural elastic recoil of the lungs and chest wall, both of which have an inherent tendency to...
Breathing01:05

Breathing

The process of breathing, inhaling and exhaling, involves the coordinated movement of the chest wall, the lungs, and the muscles that move them. Two muscle groups with important roles in breathing are the diaphragm, located directly below the lungs, and the intercostal muscles, which lie between the ribs. When the diaphragm contracts, it moves downward, increasing the volume of the thoracic cavity and creating more room for the lungs to expand. When the intercostal muscles contract, the ribs...